Loading stock data…
Genmab A/S (GMAB)
$26.12-0.02 (-0.08%)
Market ClosedLast close Jun 26
Genmab A/S, a biotechnology company, develops antibody-based products and product candidates for the treatment of cancer and other diseases in Denmark.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Genmab A/S in the Healthcare sector is trading at $26.12 with a market capitalization of $14.8B. Wall Street consensus targets $36.82 (11 analysts), implying a +41.0% move over the next 12 months. The stock is currently 26% below its 52-week high of $35.43, remaining 10.6% below its 200-day moving average. On fundamentals, Piotroski 4/9 shows mixed financial quality. The Whystock Score of 50/100 suggests a balanced risk-reward profile.
Ecosystem Influences
Sell-side targets imply +41.0% upside over 12 months
Long-term trend bearish (price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Quarterly Financials
| Metric (USD) | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 |
|---|---|---|---|---|---|
| Total Revenue | $896.00M↓ | $1.06B↑ | $1.02B↑ | $925.00M↑ | $715.00M |
| Gross Profit | $831.00M↓ | $977.00M↑ | $964.00M↑ | $868.00M↑ | $673.00M |
| Operating Income | $225.00M↓ | $243.00M↓ | $459.00M↑ | $360.00M↑ | $188.00M |
| Net Income | $53.00M↑ | $31.00M↓ | $401.00M↑ | $336.00M↑ | $195.00M |
Peer Comparison
JNJUNHPFE
Fundamentals
Genmab A/S, a biotechnology company, develops antibody-based products and product candidates for the treatment of cancer and other diseases in Denmark. The company markets EPKINLY and TEPKINLY for adult patients with relapsed or refractory (R/R) diff...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$14.82B
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
-
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
14.45%
Volume
Today's trading volume
1.78M
Recent News
VERAXA Unveils Cancer Therapy Platform, Sparks Partnering Talks at BIO 2026
By Karen Roman Veraxa Biotech AG (Nasdaq: VRXA) reported in vitro proof-of-concept data validating its BiTAC-ADC platform for cancer therapies, with selective tumor cell killing while sparing healthy cells. The company will showcase partnering opportunities for its platform at the BIO International Convention in San Diego, California, taking place on June 22-25, 2026, it stated […] The post VERAXA Unveils Cancer Therapy Platform, Sparks Partnering Talks at BIO 2026 appeared first on ExecEdge.
Genmab’s EPCORE Data Deepens Lymphoma Profile As Investors Weigh Upside
Genmab (CPSE:GMAB) released new subgroup data from its pivotal Phase 3 EPCORE FL-1 trial of epcoritamab plus rituximab and lenalidomide in relapsed or refractory follicular lymphoma. The company also reported positive results from additional EPCORE studies in elderly patients with newly diagnosed diffuse large B cell lymphoma who are not candidates for standard chemotherapy. The findings indicate sustained efficacy and manageable safety for epcoritamab in both combination and monotherapy...
Truist Assigns Buy Rating to Genmab (GMAB)
Genmab A/S (NASDAQ:GMAB) is one of the 10 best large cap stocks under $30 with highest upside potential. On May 27, coverage of Genmab A/S (NASDAQ:GMAB) was resumed by Truist analyst Gregory Renza. The analyst reduced the price target from $48 to $40 and assigned a Buy rating to the stock. He shared an optimistic […]
Genmab (CPSE:GMAB) Valuation Check After Recent Share Price Softness And 24.6% Undervaluation Estimate
Recent performance snapshot Genmab (CPSE:GMAB) has seen mixed share price moves recently, with the stock down about 1.7% on the day and lower over the past month and past 3 months, but higher over the past year. For context, Genmab reports revenue of 3,901 million DKK and net income of 821 million DKK from its antibody focused biotechnology business, and currently carries a market value of about 103.4b DKK. See our latest analysis for Genmab. At the current share price of DKK1,684.0, Genmab’s...
Morgan Stanley Maintains an “Equal Weight” Rating on Genmab A/S (GMAB)
Genmab A/S (NASDAQ:GMAB) is one of the 8 Most Promising Biotech Stocks to Buy Now. On May 8, Morgan Stanley reduced its price goal on Genmab A/S (NASDAQ:GMAB) to $33 from $34. It maintained an “Equal Weight” rating on the shares. On May 7, Genmab A/S (NASDAQ:GMAB) reported revenue of $896 million for Q1 2026, […]